Clinical Trial Update: Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update on the safety and immunogenicity of Innocell Autologous Cellular Immunotherapy for recurrent epithelial ovarian cancer; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Innocell Autologous Cellular Immunotherapy

Snippet

Sponsor: PhotonPharma, Inc. | Conditions: Ovarian Cancer, Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer | Phase 1 | Status: RECRUITING